	Teligent, a New Jersey-based specialty generic-drug pharmaceutical company, held a formal groundbreaking ceremony for the ongoing expansion of its manufacturing and research and development complex in Buena, NJ, the company said in a July 6, 2016 press release. The $45â50 million project will increase the facility's footprint by more than 75,000 ft

, a 200% increase to current operations. Once completed, the expansion will include the installation of a new isolator-based sterile injectable manufacturing suite and will deliver a significant increase to the company's manufacturing capacity for topical pharmaceutical products.

	''We are making very good progress on our expansion, and this ceremony was an opportunity to celebrate what we are building together,'' commented Teligent's president and CEO, Jason Grenfell-Gardner, in the press release. ''We continue to be on track for project completion by the end of 2017.''

Aseptic/Sterile Processing

Bio/Pharma News

Dosage Forms

Generic Drugs

Manufacturing

Parenterals

PharmTech News

Teligent is expanding its manufacturing and R&D complex in New Jersey.